Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family. It is grouped under the following drug class(es): Monoclonal antibodies. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Omnitarg, rhuMAb 2C4, pertuzumabum and Perjeta. Its PubChem SID is 481101798.
Pertuzumab
| CAS No | 380610-27-5 |
|---|---|
| Molecular Formula | N/A |
| Molecular Weight | 148,000 Daltons |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).
The listed CAS number is 380610-27-5.
The listed molecular formula is N/A.
The listed molecular weight is 148,000 Daltons.
N/A.
The source lists Omnitarg, rhuMAb 2C4, pertuzumabum and Perjeta.